This week's roundup of Houston innovators includes Sarah "Sassie" Duggleby of Venus Aerospace, Youngro Lee of Brassica, and Le Dam of myAvos. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from rocket science to fintech — recently making headlines in Houston innovation.

Sarah "Sassie" Duggleby, CEO and co-founder of Venus Aerospace

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby and her husband were living in Japan and considering a trip back to Texas and wishing there was a faster option than a full day of international travel — with their kids, no less. That's when Andrew Duggleby told Sassie that there actually might be an engine that could do that.

Flash forward a few years, and the husband-wife team has built a company around that idea. Venus Aerospace, originally founded in California, relocated to Houston in 2021 to establish their company in an ecosystem with the tools to advance their tech — and give their employees a good work-life balance, Sassie Duggleby explains on the Houston Innovators Podcast.

"We knew we had to find a location where we could test our engine and still be home for dinner," she says on the show. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner." Read more.

Youngro Lee has announced funding for his latest fintech endeavor. Photo courtesy

Youngro Lee is no stranger to shaking up the finance world with a new tech-based way of doing business. One of the founders of NextSeed, Lee's newest mission is providing "investment infrastructure as a service" with his company, Brassica, which just raised $8 million in seed funding.

“The future of finance will depend on the ability of trustworthy institutions to provide secure and seamless transitions between traditional financial services and web3 innovations while complying with strict regulations and still providing great customer experience,” says Lee in the news release.

Houston-based Mercury Fund led the round with several other investors participating. Read more.

Le Dam, CEO and founder of OptiChroniX

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

After years on the West Coast, Le Dam has returned to her adopted hometown of Houston — just in time to launch a new app dedicated to providing health resources and information to its users.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. Read more.

The myAvos app has been designed by behavioral health scientists to set users up for long, healthy lives. Photo via Canva

Houston innovator launches holistic health and cognitive care app

download now

Meet Laura. She’s not human, but she could be the key to your aging healthfully. She’s the digital wellness coach on myAvos, a groundbreaking app that launched this week from OptiChroniX.

Now meet Le Dam, the woman behind the app. Dam is a medical doctor, as well as CEO and co-founder of OptiChroniX. While practicing medicine in her birthplace of Australia, Dam realized that her life of prescribing medications to patients who were already sick was not how she had envisioned helping people. She knew that prevention, using the five pillars of healthy aging — nutrition, activity, sleep, health, and stress — was the way to keep patients fit and happy into their golden years.

She returned to California, where she lived after leaving Houston as a youth, to work at a startup with the goal of one day heading a company of her own. She met Swiss-based COO and co-founder, Rene Gilvert, on LinkedIn.

“He was looking for a medical doctor to join his startup,” Dam recalls. “We were so well aligned that we decided to join forces.” Now, the team works remotely in locations ranging from Dam’s home in Houston to Portugal.

When the pandemic happened, Dam took the opportunity to leave the Silicon Valley and work remotely from Houston, a return that she says was always her end goal.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. From there, Laura coaches them on what changes they can make to live healthier lifestyles. The app even reminds users when to take their medications and shares information with designated caregivers.

The myAvos app has a comprehensive approach to health. Screenshots via avos.health

The app has been designed by behavioral health scientists to understand why you’re not exercising enough or eating right and can offer personalized motivations to get users off the couch.

Right now, the focus is on potential dementia and cognitive impairment, says Dam, but in the future, myAvos will more holistically target all preventable chronic illnesses. But dementia is one of the major causes of disability among older people around the world and people living with it is expected to triple by 2050.

“If we can empower people with health literacy, we really believe we can prevent chronic disease,” says Dam. “Forty percent of dementia is preventable. A lot of these chronic diseases are preventable. Even diabetes can be reversible.”

And she points out that the changes that can be made to help cognitive health can affect other systems as well.

“We really want to empower the individuals,” Dam says. “If we can empower people with health literacy, we really believe we can prevent chronic disease.”

And myAvos is the key. The app is based on a subscription model, allowing users full access to a risk calculator, monthly cognitive assessments, personalized lifestyle guidance, and even fun brain games to keep them sharp. It may turn out that a visit with Laura a day will keep the doctor away long into your later years.

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.